Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 8/20 | 0.65 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1265338 | 0.87 | PIN1 (0.53) | PIN1PRKCQMAPTHTTPOLB | |
| SCHEMBL14841617 | 0.87 | PIN1 (0.62) | PIN1PRKCQSIRT5MAPTAPP | |
| SCHEMBL3854087 | 0.85 | PRKCQ (0.54) | PIN1PRKCQEGFR | |
| SCHEMBL2274362 | 0.84 | PIN1 (0.58) | PIN1PRKCQ | |
| SCHEMBL18757880 | 0.84 | NPC1 (0.62) | PIN1PRKCQEGFRMAPTHTT | |
| SCHEMBL1917607 | 0.83 | PIN1 (0.57) | PIN1PRKCQKDM4E | |
| SCHEMBL5416389 | 0.81 | STK17A (0.67) | PIN1PRKCQSIRT5MAPT | |
| SCHEMBL18319382 | 0.81 | MAPT (0.64) | PRKCQEGFRSIRT5MAPTHTT | |
| SCHEMBL1266942 | 0.81 | PRKCQ (0.57) | PIN1PRKCQMAPTPOLB | |
| SCHEMBL4384358 | 0.80 | PRKCQ (0.65) | PRKCQEGFRSIRT5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| WO-2011157397-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
| US-7560458-B2 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-14 | — | — | US | disclosed |
| US-20090036471-A1 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors | EDGARD EDDY JEAN | 2009-02-05 | — | — | US | disclosed |
| EP-1442024-B1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1658292-B1 | TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20060205721-A1 | 3-(Phenyl),5-(3-carmoylphenyl)-amino)-3H-V-triazolo(4,5-D)pyrimidine; bipolar disorder, antidepressants; antidiabetic agents; Alzheimer's disease; blood disorders; dementia; parkinson's disease; neurodegenerative diseases; genetic disorders; muscular disorders; antiinflammatory/anticarcinogenic agents | PARAGON INTELLECTUAL PROPERTIES, LLC | 2006-09-14 | — | — | US | disclosed |
| EP-1658292-A1 | TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-24 | — | — | EP | disclosed |
| US-20060063789-A1 | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | US | disclosed |
| WO-2005012307-A1 | TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| EP-1442024-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037877-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036471-A1 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors | GSK3B, GSK3A, GYS2 | PIN1 1148/4885PRKCQ 242/4885EGFR 1841/4885 |
| US-20060205721-A1 | 3-(Phenyl),5-(3-carmoylphenyl)-amino)-3H-V-triazolo(4,5-D)pyrimidine; bipolar disorder, antidepressants; antidiabetic agents; Alzheimer's disease; blood disorders; dementia; parkinson's disease; neurodegenerative diseases; genetic disorders; muscular disorders; antiinflammatory/anticarcinogenic agents | PSEN1, CHRNA3, CHRNA6 | PIN1 2520/4885PRKCQ 3019/4885EGFR 4007/4885 |
| US-20060063789-A1 | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | GSK3B, GSK3A, PHKG1 | PIN1 2845/4885PRKCQ 167/4885EGFR 1235/4885 |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | PIN1 1940/4885PRKCQ 347/4885EGFR 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.